Bright Minds work shows BMB-201 outperforms sumatriptan

Mr. Ian McDonald reports BRIGHT MINDS BIOSCIENCES ANNOUNCES BMB-201 OUTPERFORMS SUMATRIPTAN IN VALIDATED PRECLINICAL VASCULAR HEADACHE MODEL Bright Minds Biosciences Inc. has released compelling preclinical results for its investigational compound BMB-201 in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 produced statistically significant reductions in facial mechanical allodynia across both male and female cohorts at one and two hours postdose, compared with vehicle, and demonstrated greater effect sizes than sumatriptan at multiple time points. Key results: Robust efficacy versus vehicle at one and two hours in both sexes (periorbital von Frey thresholds); Benchmark comparison: BMB-201 showed greater effect sizes than sumatriptan at multiple time points and doses (for example, males: BMB-201 86 per cent versus sumatriptan 81 per cent at one hour; 53 to 64 per cent versus 44 per cent at two hours; females: BMB-201 76 to 100 per cent at one hour versus sumatriptan 56 per cent; 80 per cent at two hours versus 63 per cent); these effect sizes reflect statistically significant improvements versus vehicle (Dunnett's test); Consistent activity across sexes and aligned with a nitric oxide trigger paradigm. "BMB-201 delivered strong and reproducible activity in a stringent vascular headache model, with efficacy signals that exceeded sumatriptan at multiple time points. This further validates the use of 5-HT2 agonists in pain management," said Jan Torleif Pedersen, chief science officer of Bright Minds Biosciences. "These data, together with previously reported efficacy data from a broad range of pain models, support advancing BMB-201 toward clinical development in headache and migraine-related conditions," said Ian McDonald, chief executive officer of Bright Minds Biosciences. About BMB-201 BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A activation. As a prodrug of BMB-A39a, it exhibits minimal activity at the 5-HT2B receptor, ensuring a reduced risk of side effects. About Bright Minds Biosciences Inc. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Its pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry. We seek Safe Harbor.